<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004387.pub2" GROUP_ID="INFECTN" ID="005103011613580074" MERGED_FROM="" MODIFIED="2012-01-17 14:40:23 +0100" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2012-01-17 10:59:02 +0000" MODIFIED_BY="Anne-Marie Stephani">
<TITLE>Chlorproguanil-dapsone for treating uncomplicated malaria</TITLE>
<CONTACT>
<PERSON ID="18279" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Hasifa</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bukirwa</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>KGX0@UG.CDC.GOV</EMAIL_1>
<EMAIL_2>hbukirwa@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Makerere University Medical School</ORGANISATION>
<ADDRESS_1>Mulago Hospital Complex</ADDRESS_1>
<ADDRESS_2>PO Box 24943</ADDRESS_2>
<CITY>Kampala</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="UG">Uganda</COUNTRY>
<PHONE_1>+256 71 2668632</PHONE_1>
<PHONE_2/>
<FAX_1>+256 41 540524</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-01-17 10:59:02 +0000" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="18279" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Hasifa</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bukirwa</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>KGX0@UG.CDC.GOV</EMAIL_1>
<EMAIL_2>hbukirwa@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Makerere University Medical School</ORGANISATION>
<ADDRESS_1>Mulago Hospital Complex</ADDRESS_1>
<ADDRESS_2>PO Box 24943</ADDRESS_2>
<CITY>Kampala</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="UG">Uganda</COUNTRY>
<PHONE_1>+256 71 2668632</PHONE_1>
<PHONE_2/>
<FAX_1>+256 41 540524</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7492" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Garner</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>pgarner@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 705 3201</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 705 3364</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19574" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Julia</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Critchley</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Epidemiology</POSITION>
<EMAIL_1>J.A.Critchley@newcastle.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Health and Society</DEPARTMENT>
<ORGANISATION>Newcastle University</ORGANISATION>
<ADDRESS_1>William Leech Building</ADDRESS_1>
<ADDRESS_2>The Medical School</ADDRESS_2>
<CITY>Newcastle</CITY>
<ZIP>NE2 4HH</ZIP>
<REGION>Tyne and Wear</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 191 222 5100</PHONE_1>
<PHONE_2/>
<FAX_1>+44 191 222 8211</FAX_1>
<FAX_2>+44 191 222 6461</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-07-16 16:13:01 +0100" MODIFIED_BY="Harriet MacLehose">
<UP_TO_DATE>
<DATE DAY="14" MONTH="8" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="5" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-05 09:53:42 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-05 09:53:42 +0000" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="5" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Classification added to abstract and plain language summary; description included in "Published notes" section of review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2008-07-16 15:21:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>This review, converted to a new review format with minor editing, will no longer be updated because chlorproguanil-dapsone (LapDap) has been "withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (Dacart<SUP>TM</SUP>) versus artemether-lumefantrine (Coartem®) and confirmation of findings in a comparative trial of LapDap<SUP>TM</SUP> versus Dacart<SUP>TM</SUP>" (<LINK REF="REF-WHO-2008" TYPE="REFERENCE">WHO 2008</LINK>)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-06-30 14:42:51 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-01-17 13:37:27 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-01-17 13:36:02 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-07-15 16:50:37 +0100" MODIFIED_BY="[Empty name]">Chlorproguanil-dapsone for treating malaria</TITLE>
<SUMMARY_BODY MODIFIED="2012-01-17 13:36:02 +0000" MODIFIED_BY="[Empty name]">
<P>Chlorproguanil-dapsone was withdrawn in 2008, and the review will not be updated.</P>
<P>Using a pilot system we have categorised this review as: Historical question - no update intended. Please see "Published notes" section of the review for more details. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-01-17 13:35:51 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-01-17 13:35:51 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>Using a pilot system we have categorised this review as: Historical question - no update intended. (Please see "Published notes" section of the review for more details). </P>
<P>In Africa, malaria is often resistant to chloroquine and sulfadoxine-pyrimethamine. Chlorproguanil-dapsone is a potential alternative.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare chlorproguanil-dapsone with other antimalarial drugs for treating uncomplicated falciparum malaria. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-07-15 16:18:21 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Diseases Group Specialized Register (May 2004), CENTRAL (<I>The Cochrane Library</I> 2004, Issue 2), MEDLINE (1966 to May 2004), EMBASE (1988 to May 2004), LILACS (May 2004), Biosis Previews (1985 to May 2004), conference proceedings, and reference lists, and contacted researchers working in this field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized and quasi-randomized controlled trials comparing chlorproguanil-dapsone to other antimalarial drugs.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-07-15 15:03:43 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers independently applied the inclusion criteria, extracted data, and assessed methodological quality. We calculated the risk ratio (RR) for dichotomous data and mean difference for continuous data, and presented them with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-07-16 15:14:37 +0100" MODIFIED_BY="[Empty name]">
<P>Six trials (n = 3352) met the inclusion criteria. Chlorproguanil-dapsone (with 1.2 mg chlorproguanil) as a single dose had fewer treatment failures than chloroquine (1 trial), but more treatment failures and people with parasitaemia at day 28 than sulfadoxine-pyrimethamine (3 trials).</P>
<P>Two trials compared the three-dose chlorproguanil-dapsone (with 2 mg chlorproguanil) regimen with sulfadoxine-pyrimethamine in new attendees. There were fewer treatment failures with chlorproguanil-dapsone by day 7 (RR 0.30, 95% CI 0.19 to 0.49; n = 827, 1 trial) and day 14 (RR 0.36, 95% CI 0.24 to 0.53; n = 1709, 1 trial). Neither trial reported total failures by day 28. A further trial was carried out in participants selected because they had previously failed sulfadoxine-pyrimethamine.</P>
<P>Adverse event reporting was inconsistent between trials, but chlorproguanil-dapsone was associated with more adverse events leading to discontinuation of treatment compared with sulfadoxine-pyrimethamine (RR 4.54, 95% CI 1.74 to 11.82; n = 829, 1 trial). It was also associated with more red blood cell disorders (RR 2.86, 95% CI 1.33 to 6.13; n = 1850, 1 trial).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-07-15 16:49:35 +0100" MODIFIED_BY="[Empty name]">
<P>There are insufficient data about the effects of the current standard chlorproguanil-dapsone regimen (three-dose, 2 mg chlorproguanil). Randomized controlled trials that follow up to day 28, record adverse events, and use an intention-to-treat analysis are required to inform any policy decisions.</P>
<P>2008: We do not plan to update this review because chlorproguanil-dapsone has been withdrawn (see the 'What's new' statement).</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-18 15:51:16 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-07-16 14:57:36 +0100" MODIFIED_BY="[Empty name]">
<P>Prompt and effective malaria treatment can prevent uncomplicated malaria from developing into more severe illness. The World Health Organization (WHO) promotes this as a major component of national malaria control programmes (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>). However, identifying effective drugs or combinations of drugs is hampered by antimalarial drug resistance. This is a problem in many African countries where the disease is common and the burden is high (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>).</P>
<P>The <I>Plasmodium falciparum</I> parasite is responsible for most of the malaria burden in Africa (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>). For decades, chloroquine was the first-line treatment for falciparum malaria, but parasite resistance has lead to this being replaced (<LINK REF="REF-White-1998" TYPE="REFERENCE">White 1998</LINK>). Several East, Central, and Southern African countries (such as Malawi, Kenya, Botswana, and South Africa) have changed their national policy for first-line treatment to sulfadoxine-pyrimethamine. Other countries, such as Uganda, are using combinations of sulfadoxine-pyrimethamine and chloroquine (<LINK REF="REF-Verhoeff-1997" TYPE="REFERENCE">Verhoeff 1997</LINK>; <LINK REF="REF-D_x0027_Alessandro-2001" TYPE="REFERENCE">D'Alessandro 2001</LINK>).</P>
<P>One problem with sulfadoxine-pyrimethamine is that parasites can develop resistance to it relatively quickly. Sulfadoxine and pyrimethamine act on two different enzymes in the folate biosynthetic pathway, which are essential for the survival of the malaria parasites. Specific parts of the parasite's DNA code for these enzymes, and they can mutate in such a way that the enzyme still functions but is protected from the effect of sulfadoxine and pyrimethamine. Sulfadoxine-pyrimethamine has a long half-life, which encourages the selection of the mutant (resistant) parasites, and resistance can develop rapidly (<LINK REF="REF-Triglia-1999" TYPE="REFERENCE">Triglia 1999</LINK>). Resistance to sulfadoxine-pyrimethamine is already widespread in South-East Asia and South America, and is becoming more common in Africa (<LINK REF="REF-WHO-1988" TYPE="REFERENCE">WHO 1988</LINK>; <LINK REF="REF-Warsame-2002" TYPE="REFERENCE">Warsame 2002</LINK>).</P>
<P>A more recent and potential alternative to sulfadoxine-pyrimethamine is the combination of chlorproguanil and dapsone. Like sulfadoxine-pyrimethamine, chlorproguanil-dapsone is an antifolate drug combination (<LINK REF="REF-White-1998" TYPE="REFERENCE">White 1998</LINK>). This combination acts on two sequential steps of the <I>Plasmodium</I> (malaria parasite) folate biosynthetic pathway. First, dapsone prevents the formation of folic acid, and then chlorproguanil interferes with the conversion of folic acid to folinic acid. This theoretically means the effects of the two drugs are synergistic (<LINK REF="REF-Thompson-1972" TYPE="REFERENCE">Thompson 1972</LINK>).</P>
<P>Chlorproguanil and dapsone have both been used for malaria prophylaxis. Chlorproguanil, as Lapudrine, has been used singly whereas dapsone has been used in combination with pyrimethamine (Maloprim). In The Gambia, chlorproguanil has been used for over five years with no reported resistance developing, but there is concern over cross-resistance between chlorproguanil and pyrimethamine (<LINK REF="REF-Greenwood-1989" TYPE="REFERENCE">Greenwood 1989</LINK>; <LINK REF="REF-Allen-1990" TYPE="REFERENCE">Allen 1990</LINK>). The development of resistance to chlorproguanil-dapsone should be slow because both drugs are rapidly eliminated from the body (mean half life of dapsone is 20 to 30 hours, chlorproguanil 12 to 20 hours) and therefore exert low selection pressure for resistance (<LINK REF="REF-Curtis-2002" TYPE="REFERENCE">Curtis 2002</LINK>). However similarities in the mechanism of development of resistance between sulfadoxine-pyrimethamine and chlorproguanil-dapsone may limit the effectiveness of chlorproguanil-dapsone (<LINK REF="REF-Le-Bras-2003" TYPE="REFERENCE">Le Bras 2003</LINK>).</P>
<P>Dapsone has adverse effects (<LINK REF="REF-Thompson-1972" TYPE="REFERENCE">Thompson 1972</LINK>), including methaemoglobinaemia, haemolysis, and anaemia (red blood cell disorders). They are thought to occur after long-term continuous use and are more frequent with doses of 100 mg or more per day (<LINK REF="REF-Wolf-2002" TYPE="REFERENCE">Wolf 2002</LINK>). More serious adverse effects include agranulocytosis and hypersensitivity. Other adverse effects with dapsone include dermatitis, hepatitis, anorexia, nausea, vomiting, headache, nervousness, blurred vision, haematuria, drug fever, and psychoses (<LINK REF="REF-Ozawa-2002" TYPE="REFERENCE">Ozawa 2002</LINK>).</P>
<P>Chlorproguanil-dapsone was developed mainly for use in Africa as a replacement for the rapidly failing sulfadoxine-pyrimethamine. Chlorproguanil-dapsone (LapDap) has been approved for general use in the United Kingdom by the UK Medicines and Healthcare products Regulatory Agency, and has been launched in Zambia, Kenya, Cameroon, Ghana, and Nigeria (<LINK REF="REF-GlaxoSmithKline-2003" TYPE="REFERENCE">GlaxoSmithKline 2003</LINK>; <LINK REF="REF-ZANA-2003" TYPE="REFERENCE">ZANA 2003</LINK>). The current standard is a fixed-ratio tablet of 2.0:2.5 mg/kg (80:100 mg adult formulation and 15:18.75 mg paediatric formulation) of chlorproguanil and dapsone respectively, taken once daily for three days. However, lower doses of chlorproguanil have previously been tested.</P>
<P>We have summarized the evidence for the role of the chlorproguanil-dapsone combination for treating uncomplicated falciparum malaria. We have used the WHO's definition in order to differentiate between the uncomplicated and severe (complicated) forms of malaria (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). Our primary outcomes are positive blood slide for <I>P. falciparum </I>on day 14 and day 28. In areas of intense transmission, positive blood smears after day 14 may be the result of new infections or a recrudescence of the old infection. Polymerase chain reaction (PCR) can be used to differentiate between new and old infections.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare chlorproguanil-dapsone with other antimalarial drugs for treating uncomplicated falciparum malaria. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-18 15:51:16 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-07-15 16:18:34 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomized and quasi-randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-07-15 13:41:18 +0100" MODIFIED_BY="[Empty name]">
<P>Adults and children with microscopically confirmed uncomplicated falciparum malaria (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>).<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-07-01 16:19:16 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Chlorproguanil-dapsone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<P>Current drug regimens for treating uncomplicated falciparum malaria.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-15 16:18:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<UL>
<LI>Presence of falciparum malaria parasites on day 14.</LI>
<LI>Presence of falciparum malaria parasites on day 28, adjusted for new infection using PCR analysis.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary</HEADING>
<UL>
<LI>Parasite clearance time.</LI>
<LI>Time to fever clearance.</LI>
<LI>Treatment failure (early treatment failure, late treatment failure (late clinical failure, and late parasitological failure) (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>; see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for definitions).</LI>
<LI>Use of antipyretic (paracetamol, other).</LI>
<LI>Mean haemoglobin.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<UL>
<LI>Serious adverse events: adverse events that lead to death, require hospitalization or prolongation of existing hospitalization, are life threatening, or result in persistent or significant disability or incapacity.</LI>
<LI>Adverse events that require the discontinuation of treatment.</LI>
<LI>Number of people experiencing adverse events.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-15 16:17:52 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<SUBSECTION>
<HEADING LEVEL="3">Databases</HEADING>
<P>We searched the following databases using the search terms and strategy described in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>: Cochrane Infectious Diseases Group Specialized Register (May 2004); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library </I>(2004, Issue 2); MEDLINE (1966 to May 2004); EMBASE (1988 to May 2004); LILACS (May 2004); and Biosis Previews (1985 to May 2004).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Conference proceedings</HEADING>
<P>We searched the following conference proceedings for relevant abstracts: Third European Congress on Tropical Medicine and International Health, Lisbon, Portugal, 8 to 11 September 2002; and The Third Multilateral Initiative on Malaria Pan-African Conference, Arusha, Tanzania, 18 to 22 November 2002.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Researchers and pharmaceutical companies</HEADING>
<P>We contacted scientists working in the field of malaria, and GlaxoSmithKline, the pharmaceutical company that manufactures chlorproguanil-dapsone (LapDap), for any unpublished trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reference lists</HEADING>
<P>We also checked the reference lists of all trials identified by the above methods.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-18 15:51:16 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-06-24 14:44:44 +0100" MODIFIED_BY="[Empty name]">
<P>Hasifa Bukirwa (HB) scanned the results of the literature search, retrieved potentially relevant trials, and checked the eligibility with Julia Critchley (JC) using a standard form. We resolved ambiguity by discussion or by contacting the authors for clarification and additional information.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-16 14:22:26 +0100" MODIFIED_BY="[Empty name]">
<P>HB and JC independently extracted trial characteristics and data. Where the number randomized and the numbers analysed were inconsistent, we calculated the percentage loss-to-follow-up and reported this in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. We had intended to primarily consider trials with intention-to-treat analysis, but only two trials had any outcomes analysed in this way (<LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>; <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>).</P>
<P>For dichotomous outcomes, we recorded the number of participants experiencing the event in each group of the trial. For continuous outcomes, we extracted the arithmetic means and standard deviations for each group.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-15 13:41:19 +0100" MODIFIED_BY="[Empty name]">
<P>HB and JC assessed the methodological quality of the included trials using generation of allocation sequence, allocation concealment, blinding of the participants and clinicians, and loss to follow up. We have classed generation of allocation sequence and allocation concealment as adequate, inadequate, or unclear according to <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>. We considered loss to follow up as adequate (acceptable) if it was 10% or lower. We classed blinding as open (all parties are aware of treatment), single blind (participant or care provider/assessor is aware of the treatment given), or double blind (trial uses a placebo or a double dummy technique such that neither the participant or care provider/assessor know which treatment is given).</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-18 15:51:16 +0100" MODIFIED_BY="[Empty name]">
<P>We analysed data using <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK>. We calculated the risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data, and presented both with 95% confidence intervals (CI). We assessed heterogeneity among included trials by visually inspecting forest plots and carrying out a chi-squared test for heterogeneity (statistical significance at 10% level). We have stratified analyses according to dosing regimen of chlorproguanil-dapsone. We used the fixed-effect model to pool data because we did not detect heterogeneity.</P>
<P>Although we planned to carry out subgroup analyses based on the following subgroups, we did not perform this because few trials were identified. This may be possible in future updates of this review.<BR/>
</P>
<UL>
<LI>Participant age (&#8804; 5 years versus &gt; 5 years).</LI>
<LI>Setting of the trial: (1) high versus low endemicity (high = hyperendemicity or holoendemicity and low = hypoendemicity or mesoendemicity); and (2) level of resistance to the comparator drug.</LI>
</UL>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-16 15:14:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-07-16 15:00:07 +0100" MODIFIED_BY="[Empty name]">
<P>Six trials (n = 3352) met our inclusion criteria ('<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). We excluded two trials ('<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>') and one trial is ongoing ('<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>').</P>
<P>Three of the included trials were multicentred (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>; <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>), and because the sites for <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK> and <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> were in different countries, we have reported the results from each centre separately by labelling each site by country, for example <LINK REF="STD-Sulo_x002d_Kenya" TYPE="STUDY">Sulo-Kenya</LINK> and <LINK REF="STD-Alloueche_x002d_Gabon" TYPE="STUDY">Alloueche-Gabon</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Source of funding</HEADING>
<P>The Wellcome Trust and African Medical &amp; Research Foundation (AMREF) funded <LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>. <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK> did not state the source of funding. The WHO and the Wellcome Trust funded <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>. The LapDap Product Development Team (PDT), which includes GlaxoSmithKline Pharmaceuticals, funded <LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>. The WHO and GlaxoSmithKline Pharmaceuticals funded <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>, and along with the Department for International Development (UK) also funded <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Location and participants</HEADING>
<P>All the trial sites were conducted in areas of high malaria transmission in Africa: five in Kenya (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK> (Kilifi and Entasopia); <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>; <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>; <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>); two in Malawi (<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>) and Tanzania (<LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>); one in Gabon (<LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>); and one in Nigeria (<LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>).</P>
<P>Four trials included children aged between 1 and 6 years, one included children aged 3 to 13 years, and one included schoolgirls and pregnant women (<LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>).</P>
<P>One trial compared chlorproguanil-dapsone with sulfadoxine-pyrimethamine in participants who had already failed on sulfadoxine-pyrimethamine (<LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intervention</HEADING>
<P>All trials compared chlorproguanil-dapsone with sulfadoxine-pyrimethamine. One trial also included a chloroquine arm ( <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dose and regimen</HEADING>
<P>Dose and regimen varied across trials. Two trials used 1.2 mg/kg chlorproguanil and 2.4 mg/kg dapsone: <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK> administered it as a single dose; and <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK> administered it as a single dose in one group and as daily dose for three days in another group. <LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK> used a single dose of 1.2 mg/kg chlorproguanil and 8 mg/kg dapsone in Kilifi, and 1.2 mg/kg chlorproguanil and 2.4 mg dapsone in Entasopia. The 1.2 mg/kg chlorproguanil dose used in <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>, <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>, and <LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK> is lower than the dose in the currently standard fixed-ratio tablet and as used in the other three trials. Three trials used 2 mg/kg chlorproguanil and 2.5 mg/kg dapsone for three days (<LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>; <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Length of follow up</HEADING>
<P>Length of follow up ranged from seven days to one year (<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>), although <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK> only reported on review outcomes (treatment failure and adverse events) at day 7. Three trials followed participants up to day 28 (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>; <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>; <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>), but none of these used the current standard dosing schedule. <LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK> and <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK> reported outcomes at day 7, and <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> up to day 14.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Resistance</HEADING>
<P>Resistance to the comparator drug is mentioned in four trials: resistance to sulfadoxine-pyrimethamine was low in Kenya (Kilifi) (<LINK REF="STD-Sulo_x002d_Kenya" TYPE="STUDY">Sulo-Kenya</LINK>); present to some extent in Malawi (Blantyre) (<LINK REF="STD-Sulo_x002d_Malawi" TYPE="STUDY">Sulo-Malawi</LINK>); and high in the Tanzania trial (<LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>). Resistance to chloroquine was high in Kenya (<LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>), but the level of resistance to sulfadoxine-pyrimethamine is not clear in this trial. <LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK> and <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK> do not describe the background resistance to sulfadoxine-pyrimethamine, but it may be inferred to be low because the trials were carried out at an earlier time period in the same area as <LINK REF="STD-Sulo_x002d_Kenya" TYPE="STUDY">Sulo-Kenya</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>All but one trial reported the presence of parasites at various time points (<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>); <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> provided data on parasitaemia on request. No trials reported on parasite clearance time and time to fever clearance. We obtained data on fever at various time points from <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> on request. Treatment failure was reported by all the trials. We were unable to present data on the use of antipyretics because the only trials that mentioned them &#8722; <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK> and <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK> &#8722; either gave them uniformly or did not give sufficient detail to allow further analyses. All trials mentioned adverse events, but only some described the procedure to identify them.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-16 15:00:49 +0100" MODIFIED_BY="[Empty name]">
<P>The methodological quality of the included trials is summarized in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
<P>Generation of allocation sequence was adequate in three trials, and inadequate in the trials that allocated treatment to women in blocks of three according to the order that they came in (<LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>) and the two that used alternate allocation (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>; <LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>).</P>
<P>For allocation concealment, three trials used adequate methods (<LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>; <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>), and three used inadequate methods (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>; <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>; <LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>).</P>
<P>For blinding, the three trials with adequate allocation concealment also concealed the allocation to the participants and to the assessors. Two trials had no blinding, and one did not describe methods for blinding (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>).</P>
<P>For losses to follow up, no trial included all the enrolled participants in the final analysis. Losses to follow up were less than 10% in four trials (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>; <LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>; <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>), 13.4% in <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>, and over 18% in <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-16 15:14:52 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">One-dose chlorproguanil-dapsone regimen (with 1.2 mg chlorproguanil)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Versus chloroquine</HEADING>
<P>One trial with a 28-day follow up assessed this regimen (<LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitaemia</HEADING>
<P>Parasitaemia tended to be lower with chlorproguanil-dapsone at days 7, 14, 21, and 28 (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). However, this was not statistically significant for the two primary review outcomes of day 14 (RR 0.55, 95% CI 0.17 to 1.80; n = 153) and day 28 (RR 0.77, 95% CI 0.34 to 1.74; n = 110).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure by day 28</HEADING>
<P>Chlorproguanil-dapsone had fewer treatment failures than chloroquine (RR 0.41, 95% CI 0.26 to 0.63; n = 165, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>This trial did not describe any procedure to identify adverse events, and none were reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Versus sulfadoxine-pyrimethamine</HEADING>
<P>Three trials compared a one-dose regimen with sulfadoxine-pyrimethamine (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>; <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>; <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitaemia</HEADING>
<P>More participants treated with chlorproguanil-dapsone than sulfadoxine-pyrimethamine had parasitaemia by day 14 and day 28 (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>); the difference was statistically significant at day 28 (RR 3.11, 95% CI 2.28 to 4.24; n = 527).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure by day 28</HEADING>
<P>The risk of treatment failure was much higher for the chlorproguanil-dapsone group compared with the sulfadoxine-pyrimethamine group (RR 2.77, 95% CI 1.86 to 4.10; n = 547, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Only <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK> reported this, with no events with chlorproguanil-dapsone compared with three serious adverse events ("parasitaemic and admitted to hospital") in the sulfadoxine-pyrimethamine group. This was not statistically significant (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Three-dose chlorproguanil-dapsone regimen (with 1.2 mg chlorproguanil)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Versus sulfadoxine pyrimethamine</HEADING>
<P>One trial assessed this regimen (<LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitaemia</HEADING>
<P>At day 28, statistically significantly more participants treated with chlorproguanil-dapsone had parasitaemia compared with those treated with sulfadoxine-pyrimethamine (RR 2.07, 95% CI 1.41 to 3.03; n = 294, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). No results were reported for parasitaemia at day 14, and no statistically significant difference was detected at day 7 (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)<I>.</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure by day 28</HEADING>
<P>Chlorproguanil-dapsone was associated with statistically significantly more treatment failures than sulfadoxine-pyrimethamine (RR 2.27, 95% CI 1.27 to 4.05; n = 294, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean haemoglobin</HEADING>
<P>No statistically significant difference in mean haemoglobin was demonstrated between participants when assessed on days 0, 7, 14, 21, and 28 (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>One adverse event was recorded with chlorproguanil-dapsone, and three serious adverse events ("parasitaemic and admitted to hospital") with sulfadoxine-pyrimethamine; the difference was not statistically significant (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Three-dose chlorproguanil-dapsone regimen (with 2.0 mg chlorproguanil)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Versus sulfadoxine-pyrimethamine (previous sulfadoxine-pyrimethamine failures)</HEADING>
<P>One trial examined people who had failed on sulfadoxine-pyrimethamine and needed re-treatment (<LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitaemia</HEADING>
<P>No results were available for day 14 or day 28, but by day 7 chlorproguanil-dapsone was statistically significantly better at clearing parasites than sulfadoxine-pyrimethamine (RR 0.11, 95% CI 0.04 to 0.34; n = 90, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure by day 7</HEADING>
<P>There were statistically significantly fewer treatment failures with chlorproguanil-dapsone by day 7 (RR 0.11, 95% CI 0.04 to 0.33; n = 92, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure by day 28</HEADING>
<P>This was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Only one adverse event, which occurred in the sulfadoxine-pyrimethamine group, was reported; and the difference in the number of adverse events was not statistically significantly different (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Versus sulfadoxine-pyrimethamine (new attendees)</HEADING>
<P>Two trials assessed this regimen (<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Parasitaemia</HEADING>
<P>
<LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> reported that parasitaemia was statistically significantly lower with chlorproguanil-dapsone at day 7 (RR 0.31, 95% CI 0.15 to 0.63; n = 1850) and day 14 (RR 0.56, 95% CI 0.37 to 0.85; n = 1850); see <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Presence of fever</HEADING>
<P>
<LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> reported no statistically significant difference in the presence of fever (defined as temperature &#8805; 37.5 ºC) at day 7 (RR 0.77, 95% CI 0.42 to 1.42; n = 1850) or day 14 (RR 1.58, 95% CI 0.79 to 3.17; n = 1850); see <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure by day 7</HEADING>
<P>
<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK> reported that chlorproguanil-dapsone was associated with statistically significantly fewer treatment failures than sulfadoxine-pyrimethamine (RR 0.30, 0.19 to 0.49; n = 827, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure by day 14</HEADING>
<P>
<LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> reported that chlorproguanil-dapsone was associated with statistically significantly fewer treatment failures than sulfadoxine-pyrimethamine (RR 0.36, 95% CI 0.24 to 0.53; n = 1709, <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK> did not report this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure by day 28</HEADING>
<P>Neither trial reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean haemoglobin</HEADING>
<P>
<LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> assessed mean haemoglobin on days 0, 3, 7, and 14 (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). Day 14 haemoglobin was only measured for a small number of participants whose day 7 results caused concern. Mean haemoglobin tended to be lower for participants on chlorproguanil-dapsone than sulfadoxine-pyrimethamine at each time point, but this was statistically significant only at day 7 (MD -0.40 g/dL, 95% CI -0.62 to -0.18; n = 1701).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Adverse events recorded included vomiting, diarrhoea, anorexia, abdominal pain, pneumonia, severe malaria, skin rash, red blood cell disorders, gastrointestinal disorders, and death; see <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK> and <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>. There were no statistically significant differences in the number of participants on chlorproguanil-dapsone reporting any adverse event compared with sulfadoxine-pyrimethamine (RR 0.97, 95% CI 0.87 to 1.09; n = 2679).</P>
<P>Both trials reported serious adverse events. <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK> reported severe malaria leading to hospitalization (n = 60) and death (n = 1), with no statistically significant difference between the groups (RR 0.99, 95% CI 0.61 to 1.61, n = 829). <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> defined serious adverse events as serious "Treatment Emergent Signs and Symptoms (TESS)" (see <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>), and also reported no statistically significant difference between the two groups (RR 1.00, 95% CI 0.34 to 2.97; n = 1850), although serious red blood cells disorders appeared more common in people treated with chlorproguanil-dapsone.</P>
<P>
<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK> reported on adverse events leading to discontinuation of treatment, and that they were more common with chlorproguanil-dapsone than sulfadoxine-pyrimethamine (RR 4.54, 95% CI 1.74 to 11.82; n = 829).</P>
<P>The primary outcome for <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK> was safety and accordingly provided more adverse event data than the other trials (see<I> </I>
<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). There were more TESS probably related to the intervention in the chlorproguanil-dapsone group (RR 1.62, 95% CI 1.09 to 2.40; n = 1850). The most commonly reported adverse events were red blood cells disorders. These were also more common on chlorproguanil-dapsone compared with sulfadoxine-pyrimethamine (80/1480 on chlorproguanil-dapsone, 7/370 on sulfadoxine-pyrimethamine; RR 2.86, 95% CI 1.33 to 6.13, n = 1850). Clinically significant methaemoglobinaemia (defined as values exceeding 10%) was also seen far more frequently on chlorproguanil-dapsone compared with sulfadoxine-pyrimethamine, but this was only measured in one site (Kenya) and was not statistically significant (RR 15.78, 95% CI 0.97 to 257.15). There was a statistically significant difference in mean methaemoglobin (reported as a percentage of total haemoglobin) on day three in favour of sulfadoxine-pyrimethamine (MD 3.8 g/dL, 95% CI 3.4 to 4.2). There was a tendency for anaemia, haemolysis, and haemolytic anaemia to be more common in participants treated with chlorproguanil-dapsone, but these were not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-16 15:02:50 +0100" MODIFIED_BY="[Empty name]">
<P>The trials were of variable methodological quality. Three trials had adequate generation of allocation sequence, allocation concealment, and double blinding (<LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>; <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>), but only two of these had losses to follow up of less than 10% (<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>). Only two trials carried out any intention-to-treat analyses (<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>). <LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK> was carried out with participants who had already failed on sulfadoxine-pyrimethamine, and it cannot be regarded as a first-line comparison between chlorproguanil-dapsone and sulfadoxine-pyrimethamine.</P>
<P>Three trials using the lower dose of chlorproguanil (1.2 mg) examined day 28 parasitaemia and treatment failure (<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>; <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>; <LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>). The results show that both the one-dose regimen (3 trials) and three-dose regimen (1 trial) were generally less effective than one-dose sulfadoxine-pyrimethamine regimen.</P>
<P>One trial using the current standard dosing regimen (with 2 mg chlorproguanil) compared this with sulfadoxine-pyrimethamine in participants who were selected on the basis of previous failure to sulfadoxine-pyrimethamine (<LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>). It is therefore difficult to draw any conclusions about comparative effectiveness of these two drugs given that the participants selected are more likely to have infections resistant to sulfadoxine-pyrimethamine.</P>
<P>No information is available at 28 days using the current standard dosing regimen (with 2 mg chlorproguanil) for parasitaemia or treatment failure by day 28. One trial measured this according to the stated methods (<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>), but did not report results for it; and the most recent trial, <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>, stopped follow up at day 14. Some recent evidence suggests day 14 treatment failure may have no predictive value in identifying true failures (<LINK REF="REF-Stepniewska-2004" TYPE="REFERENCE">Stepniewska 2004</LINK>). There is thus currently insufficient evidence to be clear whether chlorproguanil-dapsone is superior or inferior to sulfadoxine-pyrimethamine.</P>
<P>All the trials mentioned adverse events, but only two described the procedure to assess them (<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>; <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>), which creates uncertainty over the completeness of these data. Also, the day of treatment when adverse events occurred were not always reported, and thus it was not possible to report this information in this review. Serious adverse events tended to be commoner with chlorproguanil-dapsone, but overall this was not statistically significant. Red blood cells disorders were more common in participants treated with chlorproguanil-dapsone, and <LINK REF="REF-Looareesuwan-2004" TYPE="REFERENCE">Looareesuwan 2004</LINK> comments on aspects of safety in a <I>Lancet</I> editorial.</P>
<P>Although <LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK> included pregnant women, it is still not possible to conclusively determine the effectiveness and safety of chlorproguanil-dapsone in this group because participants were a mixed group, numbers for important outcomes were sometimes too few, and adverse event outcomes were not reported.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-07-16 15:06:38 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-07-16 15:04:08 +0100" MODIFIED_BY="[Empty name]">
<P>No data are available after day 14 for the current standard chlorproguanil-dapsone regimen (three doses, 2 mg chlorproguanil), and therefore there is insufficient evidence to know whether this drug is inferior or superior to current regimens of chloroquine or sulfadoxine-pyrimethamine.</P>
<P>2008: Chlorproguanil-dapsone was withdrawn in 2008 (see the 'What's new' statement), and the review will not be updated.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-07-16 15:06:38 +0100" MODIFIED_BY="[Empty name]">
<P>2008: Chlorproguanil-dapsone was withdrawn in 2008 (see the 'What's new' statement).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Hasifa Bukirwa developed this review during a 12-month training Fellowship organized by the Effective Health Care Alliance Programme (EHCAP) at the Liverpool School of Tropical Medicine, funded by the Department for International Development (UK).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Paul Garner is employed by the University of Liverpool, who also employ academics involved with the development of the co-formulated commercial preparation of this combination. Julia Critchley is employed by the Liverpool School of Tropical Medicine, who also employ academics involved with the development of this combination.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Hasifa Bukirwa extracted and analysed data, and drafted the review. Julia Critchley extracted data, and along with Paul Garner, wrote the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-06-30 14:42:32 +0100" MODIFIED_BY="[Empty name]">
<P>Types of outcomes: We have added "mean haemoglobin" because of its clinical importance, and used the mean difference to present these data.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-01-17 13:37:27 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>2012, Issue 2: Review status: Historical question - no update intended. Chlorproguanil-dapsone was withdrawn in 2008.</P>
<P>The Cochrane Infectious Diseases Group assesses Review Status using a pilot system to help the reader understand whether the review concerns a current question, and is up to date. We report on:</P>
<P>1. The question the review addresses. Is it a:</P>
<UL>
<LI>
<B>Historical question</B>, where the intervention or policy has been superseded by new medical developments (such as a new drug); or a</LI>
<LI>
<B>Current question</B>, which is still relevant to current policy or practice.</LI>
</UL>
<P>
<B>2. </B>Whether the review is up to date. Is the review:</P>
<UL>
<LI>
<B>Up to date</B>;</LI>
<LI>
<B>Update pending</B>; or</LI>
<LI>
<B>No update intended</B>.</LI>
</UL>
<P>We then provide comment of the review status, to help explain the categories selected.</P>
<P/>
<P>For the most up-to-date information regarding malaria treatments, please see: Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007483. DOI: 10.1002/14651858.CD007483.pub2.)</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-18 15:51:16 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-07-15 15:57:08 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-06-30 14:33:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Alloueche-2004" MODIFIED="2008-06-30 14:33:25 +0100" MODIFIED_BY="[Empty name]" NAME="Alloueche 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-06-30 14:33:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, et al</AU>
<TI>Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9424</NO>
<PG>1843-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Alloueche_x002d_Gabon" NAME="Alloueche-Gabon" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Gabon site of Alloueche 2004 multicentre trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Alloueche_x002d_Kenya" NAME="Alloueche-Kenya" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Kenya site of Alloueche 2004 multicentre trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Alloueche_x002d_Malawi" NAME="Alloueche-Malawi" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malawi site of Alloueche 2004 multicentre trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Alloueche_x002d_Nigeria" NAME="Alloueche-Nigeria" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nigeria site of Alloueche 2004 multicentre trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Alloueche_x002d_Tanzania" NAME="Alloueche-Tanzania" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Tanzania site of Alloueche 2004 multicentre trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amukoye-1997" MODIFIED="2008-06-30 14:33:33 +0100" MODIFIED_BY="[Empty name]" NAME="Amukoye 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-06-30 14:33:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amukoye E, Winstanley PA, Watkins WM, Snow RW, Hatcher J, Mosobo M, et al</AU>
<TI>Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>10</NO>
<PG>2261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keuter-1990" MODIFIED="2008-06-30 14:33:43 +0100" MODIFIED_BY="[Empty name]" NAME="Keuter 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-06-30 14:33:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keuter M, van Eijk A, Hoogstrate M, Raasveld M, van de Ree M, Ngwawe WA, et al</AU>
<TI>Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega District, Kenya</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>301</VL>
<NO>6750</NO>
<PG>466-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mutabingwa-2001" MODIFIED="2008-06-30 14:33:39 +0100" MODIFIED_BY="[Empty name]" NAME="Mutabingwa 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-30 14:33:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, et al</AU>
<TI>Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<NO>9289</NO>
<PG>1218-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulo-2002" MODIFIED="2008-06-30 14:33:47 +0100" MODIFIED_BY="[Empty name]" NAME="Sulo 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-06-30 14:33:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME, et al</AU>
<TI>Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9340</NO>
<PG>1136-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulo_x002d_Kenya" NAME="Sulo-Kenya" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenya site of Sulo 2002 multicentre trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulo_x002d_Malawi" NAME="Sulo-Malawi" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malawi site of Sulo 2002 multicentre trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watkins-1988" MODIFIED="2008-06-30 14:33:51 +0100" MODIFIED_BY="[Empty name]" NAME="Watkins 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-06-30 14:33:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watkins WM, Brandling-Bennett AD, Nevill CG, Carter JY, Boriga DA, Howells RE, et al</AU>
<TI>Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>3</NO>
<PG>398-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Trigg-1997" NAME="Trigg 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trigg JK, Mbwana H, Chambo O, Hills E, Watkins W, Curtis CF</AU>
<TI>Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in northeast Tanzania and a test of chlorproguanil/dapsone</TI>
<SO>Acta Tropica</SO>
<YR>1997</YR>
<VL>63</VL>
<NO>2-3</NO>
<PG>185-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilairatana-1997" NAME="Wilairatana 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilairatana P, Kyle DE, Looareesuwan S, Chinwongprom K, Amradee S, White NJ, et al</AU>
<TI>Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>2</NO>
<PG>125-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-07-15 14:46:07 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2008-07-15 15:57:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lalloo-2004" MODIFIED="2008-07-15 15:57:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lalloo 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-15 15:57:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lalloo D, Winstanley, P, Molyneux M, Wootton D, Phiri N</AU>
<TI>A pragmatic trial examining the effect of compliance upon clinical effectiveness and cost effectiveness of LapDap<SUP>TM</SUP> (CPG-DDS) when compared to sulfadoxine-pyrimethamine (SP) and Co-artem (AM-LU) for the treatment of uncomplicated falciparum malaria in Malawi</TI>
<SO>Unpublished</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-18 15:51:16 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-18 15:51:16 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2008-07-01 16:04:40 +0100" MODIFIED_BY="[Empty name]" NAME="Alderson 2004" TYPE="OTHER">
<AU>Alderson P, Green S, Higgins J, editors</AU>
<TI>Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Reviewer's Handbook 4.2.2 [updated March 2004]; Appendix 5b</TI>
<SO>In: The Cochrane Library. The Cochrane Collaboration. Chichester, UK: John Wiley &amp; Sons, Ltd.; 2004, Issue 2</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-1990" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 1990" TYPE="JOURNAL_ARTICLE">
<AU>Allen SJ, Otoo LN, Cooke GA, O'Donnell A, Greenwood BM</AU>
<TI>Sensitivity of Plasmodium falciparum to chlorproguanil in Gambian children after five years of continuous chemoprophylaxis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>2</NO>
<PG>218</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtis-2002" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Curtis 2002" TYPE="JOURNAL_ARTICLE">
<AU>Curtis J, Maxwell CA, Msuya FHM, Mkongewa S, Alloueche A, Warhurst DC</AU>
<TI>Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2002</YR>
<VL>186</VL>
<NO>12</NO>
<PG>1861-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Alessandro-2001" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="D'Alessandro 2001" TYPE="JOURNAL_ARTICLE">
<AU>D'Alessandro U, Buttiens H</AU>
<TI>History and importance of antimalarial drug resistance</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2001</YR>
<VL>6</VL>
<NO>11</NO>
<PG>845-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GlaxoSmithKline-2003" MODIFIED="2008-07-18 15:49:36 +0100" MODIFIED_BY="[Empty name]" NAME="GlaxoSmithKline 2003" TYPE="OTHER">
<AU>GlaxoSmithKline</AU>
<TI>MHRA approves anti-malarial LapDap</TI>
<SO>www.gsk.com/press_archive/press2003/press_08062003.htm</SO>
<YR>(accessed 16 October 2003)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenwood-1989" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Greenwood 1989" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood BM, Greenwood AM, Smith AW, Menon A, Bradley AK, Snow RW, et al</AU>
<TI>A comparative study of Lapudrine (chlorproguanil) and Maloprim (pyrimethamine and dapsone) as chemoprophylactics against malaria in Gambian children</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>2</NO>
<PG>182-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in healthcare: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Le-Bras-2003" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Le Bras 2003" TYPE="JOURNAL_ARTICLE">
<AU>Le Bras J, Durand R</AU>
<TI>The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum</TI>
<SO>Fundamental &amp; Clinical Pharmacology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>2</NO>
<PG>147-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Looareesuwan-2004" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Looareesuwan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Imwong M, Wilairatana P</AU>
<TI>Chlorproguanil-dapsone for malaria in Africa</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9424</NO>
<PG>1838-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ozawa-2002" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Ozawa 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ozawa H, Maruyama Y</AU>
<TI>A 50-year history of new drugs in Japan: the developments of antileprosy drugs and their epidemiological aspects</TI>
<TO>Oyo Yakuri Kenkyurai</TO>
<SO>Yakushigaku Zasshi</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>1</NO>
<PG>76-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5" MODIFIED="2008-07-18 15:51:16 +0100" MODIFIED_BY="[Empty name]" NAME="Review Manager 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen, England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stepniewska-2004" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Stepniewska 2004" TYPE="OTHER">
<AU>Stepniewska K, Taylor WRJ, Mayxay M, Smithius F, Guthmann JP, Barnes K , et al</AU>
<TI>The in vivo assessment of antimalarial drug efficacy in falciparum malaria</TI>
<SO>Unpublished</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1972" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Thompson 1972" TYPE="BOOK">
<AU>Thompson PE, Werbel LM</AU>
<SO>Antimalarial agents: chemistry and pharmacology</SO>
<YR>1972</YR>
<VL>12</VL>
<PB>Academic Press</PB>
<CY>New York and London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Triglia-1999" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Triglia 1999" TYPE="JOURNAL_ARTICLE">
<AU>Triglia T, Cowman AF</AU>
<TI>Mechanism of resistance to sulfa drugs</TI>
<SO>Drug Resistance Updates</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verhoeff-1997" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Verhoeff 1997" TYPE="JOURNAL_ARTICLE">
<AU>Verhoeff FH, Brabin BJ, Masache P, Kachale B, Kazembe P, Van der Kaay HJ</AU>
<TI>Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine in southern Malawi</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>2</NO>
<PG>133-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warsame-2002" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Warsame 2002" TYPE="JOURNAL_ARTICLE">
<AU>Warsame M, Abdillahi A, Nur Duale A, Nur Ismail A, Hassan AM, Mohamed A, et al</AU>
<TI>Therapeutic efficacy of chloroquine and sulfadoxine/pyrimethamine agaisnt Plasmodium falciparum infection in Somalia</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2002</YR>
<VL>80</VL>
<NO>9</NO>
<PG>704-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1998" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="White 1998" TYPE="JOURNAL_ARTICLE">
<AU>White NJ</AU>
<TI>Drug resistance in malaria</TI>
<SO>British Medical Bulletin</SO>
<YR>1998</YR>
<VL>54</VL>
<NO>3</NO>
<PG>703-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1988" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1988" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Development of recommendations for the protection of short-stay travellers to malaria endemic areas: Memorandum from two WHO Meetings</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1988</YR>
<VL>66</VL>
<NO>2</NO>
<PG>177-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1999" MODIFIED="2008-07-18 15:48:16 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1999" TYPE="BOOK_SECTION">
<AU>World Health Organization</AU>
<TI>Rolling back malaria</TI>
<SO>The world health report : 1999 : Making a difference</SO>
<YR>1999</YR>
<PG>49-63</PG>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" MODIFIED="2008-07-18 15:50:35 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2000" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO Expert Committee on Malaria. WHO Technical Report Series 892</TI>
<SO>mosquito.who.int/docs/ecr20.pdf</SO>
<YR>(accessed 10 March 2003)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Severe malaria in the African region: results of a multicentre study</TI>
<SO>Malaria Liason Bulletin of the Malaria Programme WHO/AFRO</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2008-07-01 16:04:40 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2002" TYPE="BOOK">
<AU>World Health Organization. Cluster on Communicable Diseases</AU>
<SO>Monitoring antimalarial drug resistance : report of a WHO consultation, Geneva, Switzerland, 3-5 December 2001</SO>
<YR>2002</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2008" MODIFIED="2008-07-15 14:45:26 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2008" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Antimalarial chlorproguanil-dapsone (LapDap&#8482;) withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (Dacart&#8482;) versus artemether-lumefantrine(Coartem®) and confirmation of findings in a comparative trial of LapDap&#8482; versus Dacart&#8482;</TI>
<SO>Information Exchange System Alert No. 117 (www.who.int/medicines/publications/drugalerts/Alert_117_LapDap.pdf)</SO>
<YR>4 March 2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolf-2002" MODIFIED="2008-07-01 16:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Wolf 2002" TYPE="OTHER">
<AU>Wolf R, Matz H, Orion E, Tuzun B, Tuzun Y</AU>
<TI>Dapsone</TI>
<SO>Dermatology Online Journal</SO>
<YR>(accessed 23 January 2003)</YR>
<VL>8</VL>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ZANA-2003" MODIFIED="2008-07-18 15:47:47 +0100" MODIFIED_BY="[Empty name]" NAME="ZANA 2003" TYPE="OTHER">
<AU>Zambia News Agency</AU>
<TI>New anti-malaria drug launched</TI>
<SO>www.zana.gov.zm/news/viewnews.cgi?category=7&amp;id=1064068189</SO>
<YR>(accessed 16 October 2003)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-16 15:09:07 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-16 15:07:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-07-15 15:58:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alloueche-2004">
<CHAR_METHODS MODIFIED="2008-07-01 13:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial (randomized parallel design). Double placebo was used</P>
<P>Multicentre trial with sites in Gabon (<LINK REF="STD-Alloueche_x002d_Gabon" TYPE="STUDY">Alloueche-Gabon</LINK>), Kenya (<LINK REF="STD-Alloueche_x002d_Kenya" TYPE="STUDY">Alloueche-Kenya</LINK>), Malawi (<LINK REF="STD-Alloueche_x002d_Malawi" TYPE="STUDY">Alloueche-Malawi</LINK>), Nigeria (<LINK REF="STD-Alloueche_x002d_Nigeria" TYPE="STUDY">Alloueche-Nigeria</LINK>, and Tanzania (<LINK REF="STD-Alloueche_x002d_Tanzania" TYPE="STUDY">Alloueche-Tanzania</LINK>)</P>
<P>Length of follow up: 14 days</P>
<P>Intention-to-treat analysis: used for some of the safety outcomes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-15 15:58:34 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled 1850 children aged 12 to 120 months</P>
<P>Inclusion criteria: pure asexual <I>P. falciparum</I> parasitaemia 2000 to 100,000 parasites/µL blood</P>
<P>Exclusion criteria: severe malaria; parasitaemia &gt; 100,000/µL, haemoglobin &lt; 6.5 g/dL; convulsions; concomitant infection or disease; allergy to sulfonamides; antimalarial treatment within past 7 days; and use of any of interventions within past 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-24 15:44:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorproguanil (2 mg/kg) + dapsone (2.5 mg/kg), once daily for 3 days (3-dose regimen)<BR/>2. Sulfadoxine (25 mg/kg) + pyrimethamine (1.25 mg/kg), 1 dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-24 15:44:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Parasite carriage on days 3, 7, and 14<BR/>2. Haematological and biochemical tests done on days 0 and 7<BR/>3. Treatment failure<BR/>4. Treatment Emergent Signs and Symptoms (TESS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-24 15:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>Trial location: 5 African countries (Gabon, Kenya, Malawi, Nigeria, and Tanzania)</P>
<P>Trial dates: 13 March to 14 December 2000</P>
<P>Treatment failure outcome: data missing for 8% of participants in chlorproguanil-dapsone group and 7% in sulfadoxine-pyrimethamine group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-15 13:43:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alloueche_x002d_Gabon">
<CHAR_METHODS MODIFIED="2008-07-15 13:43:45 +0100" MODIFIED_BY="[Empty name]">
<P>Gabon site in <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-15 13:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-15 13:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-15 13:43:15 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-15 13:43:15 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-15 13:43:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alloueche_x002d_Kenya">
<CHAR_METHODS MODIFIED="2008-07-15 13:43:51 +0100" MODIFIED_BY="[Empty name]">
<P>Kenya site in <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-15 13:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-15 13:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-15 13:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-15 13:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-16 15:06:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alloueche_x002d_Malawi">
<CHAR_METHODS MODIFIED="2008-07-15 13:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Malawi site in <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-16 15:06:55 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 15:06:56 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-15 13:43:21 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-15 13:43:21 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-15 13:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alloueche_x002d_Nigeria">
<CHAR_METHODS MODIFIED="2008-07-15 13:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Nigeria site in <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-15 13:43:22 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-15 13:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-15 13:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-15 13:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-16 15:06:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alloueche_x002d_Tanzania">
<CHAR_METHODS MODIFIED="2008-07-15 13:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>Tanzania site in <LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-16 15:06:58 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 15:06:58 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-15 13:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-15 13:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-15 15:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amukoye-1997">
<CHAR_METHODS MODIFIED="2008-06-24 15:53:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial (randomized parallel design)</P>
<P>Length of follow up: 28 days </P>
<P>Intention-to-treat analysis: not used</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-15 15:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled 511 febrile children (6 to 71 months)</P>
<P>Inclusion criteria: children attending hospital included if well enough for outpatient management; resident within study area; capillary haemoglobin level of 5 g/dL or greater; uncomplicated pure falciparum malaria parasites between 2000 and 250,000/µL blood</P>
<P>Exclusion criteria: concurrent infection; allergy to sulfonamides; treatment with sulfadoxine-pyrimethamine or pyrimethamine-sulfalene within 2 months, or treatment with chloramphenicol, or co-trimoxazole, erythryomycin, or tetracycline within last week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-24 16:00:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorproguanil (1.2 mg/kg) + dapsone (2.4 mg/kg), 1 dose<BR/>2. Chlorproguanil (1.2 mg/kg) + dapsone (2.4 mg/kg), 3 doses over 3 days<BR/>3. Sulfadoxine (25 mg/kg) + pyrimethamine (1.25 mg/kg), 1 dose</P>
<P>Antipyretic used in all participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-24 16:00:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Fever on day 2<BR/>2. Parasite carriage on days 0, 2, 7, and trial end point<BR/>3. Mean haemoglobin (g/dL) on days 0, 2, 7, 14, 21, and 28<BR/>4. Treatment failure<BR/>5. Adverse events<BR/>6. Self-reported compliance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-24 16:01:02 +0100" MODIFIED_BY="[Empty name]">
<P>Trial location: Kenya</P>
<P>Trial dates: July 1993 to April 1995</P>
<P>Loss to follow up were withdrawals due to vomiting study medication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-16 15:07:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keuter-1990">
<CHAR_METHODS MODIFIED="2008-06-24 16:07:01 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized controlled trial (parallel design, block allocation)</P>
<P>Length of follow up: 6 weeks</P>
<P>Intention-to treat-analysis: not used</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-16 15:07:29 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled 158 adult pregnant women attending primary care hospital, and 105 non-pregnant secondary school girls of reproductive age</P>
<P>Inclusion criteria for pregnant women: 20 to 36 weeks of pregnancy; asexual parasitaemia 500 to 100,000 asexual forms/µL blood; negative urine sample for sulfonamides</P>
<P>Inclusion criteria for school girls not given</P>
<P>Exclusion criteria: none stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-24 16:07:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chloroquine base (25 mg/kg) over 3 days<BR/>2. Sulfadoxine (1500 mg) + pyrimethamine (75 mg), 1 dose<BR/>3. Chlorproguanil (1.2 mg/kg) + dapsone (2.4 mg/kg), 1 dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-24 16:07:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Parasite carriage on days 7, 14, 21, 28 up to 42<BR/>2. Mean haemoglobin and change from the start value on day 28<BR/>3. Treatment failure<BR/>4. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-24 16:07:19 +0100" MODIFIED_BY="[Empty name]">
<P>Trial location: Kenya</P>
<P>Trial dates: March to July 1988</P>
<P>Mean parasitaemia given at entry only and by gravidity (not intervention)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-01 15:27:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mutabingwa-2001">
<CHAR_METHODS MODIFIED="2008-06-24 16:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized controlled trial</P>
<P>Trial had two stages:<BR/>1. sulfadoxine-pyrimethamine used alone;<BR/>2. then either sulfadoxine-pyrimethamine or chlorproguanil-dapsone used in parallel in failures on sulfadoxine-pyrimethamine</P>
<P>Length of follow up: 7 days</P>
<P>Intention-to-treat analysis: not used</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-01 15:27:36 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled 92 febrile children &lt; 5 years old</P>
<P>Inclusion criteria: &lt; 5 years; pure infection of <I>Plasmodium falciparum</I> of at least 2000 parasites/µL; not suffering from severe and complicated malaria; able to take study drugs by oral route; parent/guardian available to give consent. (These were the inclusion criteria for the primary study. It is not clear whether they followed for the secondary study where chlorproguanil-dapsone was used. It was specified that children who failed on initial treatment with sulfadoxine-pyrimethamine and had a positive blood slide plus axillary temperature &#8805; 37.5 °C.)</P>
<P>Exclusion criteria: none stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-24 15:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorproguanil (2 mg/kg) + dapsone (2.5 mg/kg), 3 doses<BR/>2. Sulfadoxine (25 mg/kg) + pyrimethamine (1.25 mg/kg), 1 dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-24 15:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Fever clearance time<BR/>2. Parasite carriage at day 7<BR/>3. Treatment failure at day 7<BR/>4. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-01 14:22:06 +0100" MODIFIED_BY="[Empty name]">
<P>Trial location: north-east Tanzania</P>
<P>Trial dates: April 1998 to May 1999</P>
<P>North-east Tanzania has hyperendemic to holoendemic malaria transmission</P>
<P>The trial had primary and secondary study groups: primary study group was treated with sulfadoxine-pyrimethamine; participants who had a positive blood smear on day 7 and were febrile (&#8804; 37.50 °C) constituted the secondary study group; secondary study group treated alternatively with either sulfadoxine-pyrimethamine or chlorproguanil-dapsone</P>
<P>16 participants potentially eligible for secondary study were excluded after the primary stage, but no reasons given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-16 15:07:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sulo-2002">
<CHAR_METHODS MODIFIED="2008-07-01 15:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial (parallel treatment groups)</P>
<P>Multicentre trial with one arm in Kilifi, Kenya (<LINK REF="STD-Sulo_x002d_Kenya" TYPE="STUDY">Sulo-Kenya</LINK>) and other arm in Blantyre, Malawi (<LINK REF="STD-Sulo_x002d_Malawi" TYPE="STUDY">Sulo-Malawi</LINK>)</P>
<P>Length of follow up: aimed at 1 year when incidence of malaria episodes was recorded and same drug given for each episode</P>
<P>Intention-to-treat analysis: used only for treatment failure outcome</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-01 15:29:03 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled febrile children aged 3 to 71 months: 410 in Kilifi and 500 in Blantyre</P>
<P>Inclusion criteria: uncomplicated malaria; well enough for outpatient care; capillary haemoglobin at least 70 g/L; falciparum parasitaemia below 250,000/µL blood</P>
<P>Exclusion criteria: children with concurrent infection; allergy to sulfonamides; or treatment within last week with sulfadoxine-pyrimethamine, pyrimethamine-sulfalene, mefloquine, amodiaquine, halofantrine, or quinine; chloroquine treatment at an earlier date was not an exclusion criterion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-01 14:29:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorproguanil (2 mg/kg) + dapsone (2.5 mg/kg), once daily for 3 days (3-dose regimen)<BR/>2. Sulfadoxine (25 mg/kg) + pyrimethamine (1.25 mg/kg), 1 dose followed with placebo for 2 days</P>
<P>All participants were given paracetamol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-24 16:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Malaria incidence (not used in this review)<BR/>2. Development of severe malaria<BR/>3. Treatment failure<BR/>4. Completion of 1 year of follow up<BR/>5. Death<BR/>6. Severe anaemia<BR/>7. Vomiting of study medication<BR/>8. Serious adverse drug reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-16 15:07:51 +0100" MODIFIED_BY="[Empty name]">
<P>Trial location: Kilifi, Kenya and Blantyre, Malawi</P>
<P>Trial dates: July 1996 to August 1998 for the Kenya site; and January 1997 to January 1999 for the Malawi site</P>
<P>Kilifi is on the Kenyan coast with year round malaria transmission and low resistance to sulfadoxine-pyrimethamine (11.3% reported in same multicentre trial)</P>
<P>Blantyre, Malawi has year round transmission of malaria and relatively high resistance to sulfadoxine-pyrimethamine (20.2% reported in the same multicentre trial)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-15 13:44:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sulo_x002d_Kenya">
<CHAR_METHODS MODIFIED="2008-07-15 13:44:36 +0100" MODIFIED_BY="[Empty name]">
<P>Kenya site in <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-15 13:44:56 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-15 13:44:57 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-15 13:44:57 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-15 13:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-15 13:45:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sulo_x002d_Malawi">
<CHAR_METHODS MODIFIED="2008-07-15 13:44:43 +0100" MODIFIED_BY="[Empty name]">
<P>Malawi site in <LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-15 13:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-15 13:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-15 13:44:55 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-15 13:45:00 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-15 16:00:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watkins-1988">
<CHAR_METHODS MODIFIED="2008-06-24 16:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized controlled trial (parallel trial)</P>
<P>Multicentre trial: Kilifi and Entasopia, Kenya</P>
<P>Length of follow up: 28 day</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-24 16:09:48 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled 112 children between 6 to 13 years at Kilifi and 3 to 13 years at Entasopia</P>
<P>Inclusion criteria: falciparum on thick blood film; patient not acutely ill; negative Dill-Glazko test for 4-aminoquinolines and Bratton-Marshal test for sulfonamides in urine</P>
<P>Exclusion criteria: none stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-24 16:10:08 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorproguanil (1.2 mg/kg) + dapsone (8 mg/kg), 1 dose, Kilifi<BR/>2. Chlorproguanil (1.2 mg/kg) + dapsone (2.4 mg/kg), 1 dose, Entasopia<BR/>3. Chlorproguanil (1.2 mg/kg), 1 dose, Kilifi<BR/>4. Sulfadoxine (24 mg/kg) + pyrimethamine (1.2 mg/kg), 1 dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-24 16:10:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Parasite carriage at days 7, 14, 21, and 28<BR/>2. Parasite clearance time<BR/>3. Treatment failure<BR/>4. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-15 16:00:41 +0100" MODIFIED_BY="[Empty name]">
<P>Trial location: Kilifi and Entasopia, Kenya<BR/>Trial dates: March 1988 (Kilifi) and December 1988 (Entasopia)</P>
<P>Kilifi is on the east coast of Kenya with hyperendemic to holoendemic transmission<BR/>Entasopia is on the south-western wall of the Rift Valley with seasonal malaria transmission (unclear if hyperendemic)</P>
<P>Background resistance to sulfadoxine-pyrimethamine is unclear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-06-24 16:11:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-06-24 16:11:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trigg-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-24 16:11:19 +0100" MODIFIED_BY="[Empty name]">
<P>Community study from north-east Tanzania excluded because not all participants had falciparum malaria and severity was not clear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-24 16:11:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilairatana-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-24 16:11:21 +0100" MODIFIED_BY="[Empty name]">
<P>Chlorproguanil-dapsone was compared to proguanil-dapsone, itself not currently used for treating malaria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-07-15 14:46:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-07-16 15:09:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-07-16 15:09:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lalloo-2004">
<CHAR_STUDY_NAME MODIFIED="2008-07-16 15:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>A pragmatic trial examining the effect of compliance upon clinical effectiveness and cost effectiveness of LapDap (chlorproguanil-dapsone) when compared to sulfadoxine-pyrimethamine and Co-artem (artemether-lumefantrine) for the treatment of uncomplicated falciparum malaria in Malawi</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2008-06-24 16:11:30 +0100" MODIFIED_BY="[Empty name]">
<P>Adults and children &gt; 6 months (and who weigh &gt; 10 kg) who present to the outpatient department of Ndirande Health Centre with uncomplicated falciparum malaria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-24 16:11:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Chlorproguanil-dapsone will be dosed using the "graduated pole" system (the appropriate number of pre-packed tablets will be given on a height basis)<BR/>2. Sulfadoxine-pyrimethamine (standard Malawi guidelines)<BR/>3. Artemether-lumefantrine (recommended World Health Organization schedule)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-24 16:11:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adequate clinical and parasitological response on day 14 using modified World Health Organization criteria<BR/>2. Presence or absence of parasitaemia on day 28<BR/>3. Compliance with the randomized regimens</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-06-30 14:37:15 +0100" MODIFIED_BY="[Empty name]">
<P>David Lalloo (dlaloo@liverpool.ac.uk)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-06-30 14:37:28 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-06-24 15:21:17 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-06-24 15:19:19 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-16 15:09:53 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-07-15 16:01:21 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-06-25 11:26:27 +0100" MODIFIED_BY="[Empty name]">Classification of response to treatment<SUP>a</SUP>
</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Expression</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Definition</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Early treatment failure</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Development of danger signs or severe malaria on day 1, day 2, or day 3, in the presence of parasitaemia; or parasitaemia on day 2 higher than day 0 count irrespective of axillary temperature; or parasitaemia on day 3 with axillary temperature 37.5 °C or higher; or parasitaemia on day 3 of 25% of count on day 0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Late clinical failure</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Development of danger signs or severe malaria after day 3 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure; or presence of parasitaemia and axillary temperature 37.5 °C or higher on any day from day 4 to day 14, without previously meeting any of the criteria of early treatment failure</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Late parasitological failure</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Presence of parasitaemia on day 14 and axillary temperature &lt; 37.5 °C, without previously meeting any of the criteria of early treatment failure or late clinical failure</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate clinical and parasitological response</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absence of parasitaemia on day 14 irrespective of axillary temperature without previously meeting any of the criteria of early treatment failure or late clinical failure or late parasitological failure</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Source: <LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-07-16 15:09:52 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Detailed search strategies</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search set</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CIDG SR<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MEDLINE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>EMBASE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>LILACS<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Biosis Previews<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CCG-DDS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorguanide</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil-dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorguanide</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorguanide</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorguanide</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorguanide</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapudrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil/dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapudrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapudrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapudrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapudrine</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapdap</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>dapsone</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CCG-DDS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CCG-DDS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CCG-DDS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CCG-DDS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CCG-DDS</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil-dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1-4/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil-dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil-dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil-dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil-dapsone</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil/dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil/dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil/dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil/dapsone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chlorproguanil/dapsone</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapdap</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapdap</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapdap</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapdap</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lapdap</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1-8/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1-8/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1-8/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1-8/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1-8/OR</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 and 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 and 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 and 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 and 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 and 10</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>b</SUP>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>); upper case: MeSH or EMTREE heading; lower case: free text term.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-07-15 13:41:18 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>Methodological quality of included studies</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Allocation sequence</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Allocation concealed</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Blinding</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Loss to follow up</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Alloueche-2004" TYPE="STUDY">Alloueche 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Double blinded<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate (&lt; 10%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Amukoye-1997" TYPE="STUDY">Amukoye 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Double blinded<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (13.4%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Keuter-1990" TYPE="STUDY">Keuter 1990</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (3-block allocation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Open</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (&gt; 18% at 4 weeks)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mutabingwa-2001" TYPE="STUDY">Mutabingwa 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (alternate)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Open</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate (&lt; 10%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Sulo-2002" TYPE="STUDY">Sulo 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Double blinded<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate (&lt; 10%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Watkins-1988" TYPE="STUDY">Watkins 1988</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (alternate)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate (&lt; 10%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Participants, providers, and assessors blinded.<BR/>
<SUP>b</SUP>Participants and assessors blinded; provider not blinded.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2008-07-16 15:09:53 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE>Additional adverse event data from Alloueche 2004</TITLE>
<TABLE COLS="4" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Adverse event (TESS<SUP>a</SUP>)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Chlorproguanil-dapsone (n/N)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Sulfadoxine-pyrimethamine (n/N)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>RR or MD<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TESS<SUP>a </SUP>probably related to study medication</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>168/1480</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26/370</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 1.62, 95% CI 1.09 to 2.40</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Red blood cell disorders</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>80/1480</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7/370</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 2.86, 95% CI 1.33 to 6.13</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Anaemia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51/1480</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7/370</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 1.82, 95% CI 0.83 to 3.98</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methaemoglobinaemia<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22/230</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0/80</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 15.78, 95% CI 0.97 to 257.15</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Day 3 mean methaemoglobin<SUP>d </SUP>(95% confidence interval)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.2 (3.8 to 4.6), n = 301</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.4 (0.4 to 0.5), n = 77</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MD 3.8, 95% CI 3.4 to 4.2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Haemolysis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/1480</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0/370</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 3.26, 95% CI 0.18 to 57.68</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Haemolytic anaemia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4/1480</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0/370</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 2.25, 95% CI 0.12 to 41.78</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>TESS: Treatment Emergent Signs and Symptoms.<BR/>
<SUP>b</SUP>Risk ratio (RR) or mean difference (MD) presented with 95% confidence intervals (CI).<BR/>
<SUP>c</SUP>Defined as value &gt; 10%, carried out only in Kenya site.<BR/>
<SUP>d</SUP>Percentage of total haemoglobin.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-16 15:13:22 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-16 15:13:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>One-dose regimen (with 1.2 mg chlorproganil) versus chloroquine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-16 15:13:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="300" TOTAL_2="277" WEIGHT="0.0" Z="0.0">
<NAME>Parasitaemia</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloroquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloroquine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="13" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="89" WEIGHT="0.0" Z="0.0">
<NAME>Day 7</NAME>
<DICH_DATA CI_END="0.664978614463142" CI_START="0.0024254572652084496" EFFECT_SIZE="0.040160642570281124" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.17719232126831208" LOG_CI_START="-2.6152063729231605" LOG_EFFECT_SIZE="-1.3961993470957363" ORDER="213" O_E="0.0" SE="1.4321015223062499" STUDY_ID="STD-Keuter-1990" TOTAL_1="82" TOTAL_2="89" VAR="2.0509147701918784" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Day 14</NAME>
<DICH_DATA CI_END="1.8004558977628695" CI_START="0.16767747916881895" EFFECT_SIZE="0.5494505494505495" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.25538248777739325" LOG_CI_START="-0.7755252637475427" LOG_EFFECT_SIZE="-0.26007138798507473" ORDER="214" O_E="0.0" SE="0.6055603163214187" STUDY_ID="STD-Keuter-1990" TOTAL_1="78" TOTAL_2="75" VAR="0.3667032967032967" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="16" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Day 21</NAME>
<DICH_DATA CI_END="0.7319126506005688" CI_START="0.10968218367575154" EFFECT_SIZE="0.2833333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.13554074629920357" LOG_CI_START="-0.9598639117115361" LOG_EFFECT_SIZE="-0.5477023290053697" ORDER="215" O_E="0.0" SE="0.4842115078286817" STUDY_ID="STD-Keuter-1990" TOTAL_1="75" TOTAL_2="68" VAR="0.2344607843137255" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="9" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Day 28</NAME>
<DICH_DATA CI_END="1.7402627014123975" CI_START="0.3400153182913845" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.24061481216889072" LOG_CI_START="-0.4685015167825643" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="216" O_E="0.0" SE="0.41653844180852445" STUDY_ID="STD-Keuter-1990" TOTAL_1="65" TOTAL_2="45" VAR="0.1735042735042735" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloroquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloroquine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6333087302588141" CI_START="0.2643774997750221" EFFECT_SIZE="0.40918526206538663" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="47" LOG_CI_END="-0.19838452511480154" LOG_CI_START="-0.577775508866261" LOG_EFFECT_SIZE="-0.38808001699053124" ORDER="217" O_E="0.0" SE="0.22285614187126507" STUDY_ID="STD-Keuter-1990" TOTAL_1="82" TOTAL_2="83" VAR="0.04966485996974543" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-07-02 17:07:54 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>One-dose regimen (with 1.2 mg chlorproguanil) versus sulfadoxine-pyrimethamine</NAME>
<DICH_OUTCOME CHI2="12.844201601213307" CI_END="3.365014806391581" CI_START="1.9741124541685295" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5773858146888142" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="59" I2="37.7150853872903" I2_Q="40.53988452718171" ID="CMP-002.01" LOG_CI_END="0.5269869795020502" LOG_CI_START="0.29537188837101025" LOG_EFFECT_SIZE="0.41117943393653017" METHOD="MH" MODIFIED="2008-07-02 17:07:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11732384057117029" P_Q="0.1685030317747035" P_Z="3.4286095615482685E-12" Q="5.045398879811167" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="797" TOTAL_2="769" WEIGHT="400.0" Z="6.958932406034086">
<NAME>Parasitaemia</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.325379360139178" CI_END="4.363434880194647" CI_START="0.578053285239243" DF="1" EFFECT_SIZE="1.5881743819316625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="84.19067153028436" ID="CMP-002.01.01" LOG_CI_END="0.6398284989498906" LOG_CI_START="-0.2380321262529302" LOG_EFFECT_SIZE="0.20089818634848017" NO="1" P_CHI2="0.011902221479189179" P_Z="0.3696791513731873" STUDIES="3" TAU2="0.0" TOTAL_1="282" TOTAL_2="266" WEIGHT="100.0" Z="0.8970745434936551">
<NAME>Day 7</NAME>
<DICH_DATA CI_END="69.49844860705977" CI_START="1.1689040095666947" EFFECT_SIZE="9.013157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8419751100733768" LOG_CI_START="0.0677788483498916" LOG_EFFECT_SIZE="0.9548769792116343" ORDER="218" O_E="0.0" SE="1.0421716665495115" STUDY_ID="STD-Amukoye-1997" TOTAL_1="152" TOTAL_2="137" VAR="1.0861217825585863" WEIGHT="16.699447203341403"/>
<DICH_DATA CI_END="1.7751016366454824" CI_START="0.005596519291776923" EFFECT_SIZE="0.09967141292442497" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.2492232244168051" LOG_CI_START="-2.252081994843216" LOG_EFFECT_SIZE="-1.0014293852132055" ORDER="219" O_E="0.0" SE="1.4692790674538605" STUDY_ID="STD-Keuter-1990" TOTAL_1="82" TOTAL_2="90" VAR="2.158780978058086" WEIGHT="83.3005527966586"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="220" O_E="0.0" SE="0.0" STUDY_ID="STD-Watkins-1988" TOTAL_1="48" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3635239486520152" CI_END="6.763492050559224" CI_START="0.41710699861033773" DF="1" EFFECT_SIZE="1.6796130117779025" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.8301709839164335" LOG_CI_START="-0.37975252309506746" LOG_EFFECT_SIZE="0.22520923041068303" MODIFIED="2008-07-02 17:07:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5465558605392771" P_Z="0.4656126087212501" STUDIES="2" TAU2="0.0" TOTAL_1="126" TOTAL_2="124" WEIGHT="100.0" Z="0.729636176226016">
<NAME>Day 14</NAME>
<DICH_DATA CI_END="11.570006746871982" CI_START="0.4105584784410965" EFFECT_SIZE="2.1794871794871793" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0633336122039896" LOG_CI_START="-0.3866249748284025" LOG_EFFECT_SIZE="0.3383543186877935" ORDER="221" O_E="0.0" SE="0.8517128514335887" STUDY_ID="STD-Keuter-1990" TOTAL_1="78" TOTAL_2="85" VAR="0.7254147812971343" WEIGHT="63.43241727425688"/>
<DICH_DATA CI_END="12.575802069690868" CI_START="0.052494166681507554" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.099535693396548" LOG_CI_START="-1.279888954094724" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="222" O_E="0.0" SE="1.397685816278337" STUDY_ID="STD-Watkins-1988" TOTAL_1="48" TOTAL_2="39" VAR="1.9535256410256412" WEIGHT="36.56758272574313"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0012793428227806" CI_END="3.0175669535822993" CI_START="0.6838691681428415" DF="1" EFFECT_SIZE="1.4365308915445067" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" I2="0.12777081959705153" ID="CMP-002.01.03" LOG_CI_END="0.4796569149744401" LOG_CI_START="-0.1650269757482816" LOG_EFFECT_SIZE="0.15731496961307925" MODIFIED="2008-07-02 17:07:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.31700139810954575" P_Z="0.3388015178796492" STUDIES="2" TAU2="0.0" TOTAL_1="122" TOTAL_2="119" WEIGHT="100.00000000000001" Z="0.9565359988288018">
<NAME>Day 21</NAME>
<DICH_DATA CI_END="2.640384298675252" CI_START="0.4638382040544552" EFFECT_SIZE="1.1066666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.42166714150911455" LOG_CI_START="-0.3336334835403668" LOG_EFFECT_SIZE="0.04401682898437387" ORDER="223" O_E="0.0" SE="0.4436673259524579" STUDY_ID="STD-Keuter-1990" TOTAL_1="75" TOTAL_2="83" VAR="0.19684069611780453" WEIGHT="79.04538848991916"/>
<DICH_DATA CI_END="12.139384623440652" CI_START="0.5920368000005185" EFFECT_SIZE="2.6808510638297873" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.0841966717954319" LOG_CI_START="-0.227651297431741" LOG_EFFECT_SIZE="0.42827268718184547" ORDER="224" O_E="0.0" SE="0.7705859908762189" STUDY_ID="STD-Watkins-1988" TOTAL_1="47" TOTAL_2="36" VAR="0.5938027693346841" WEIGHT="20.95461151008085"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6740137540658165" CI_END="4.24136699859249" CI_START="2.284771965138426" DF="2" EFFECT_SIZE="3.112965854654919" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="39" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="0.6275058528812383" LOG_CI_START="0.35884286120060593" LOG_EFFECT_SIZE="0.49317435704092205" MODIFIED="2008-07-02 17:07:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7139040033378863" P_Z="6.21586465311508E-13" STUDIES="3" TAU2="0.0" TOTAL_1="267" TOTAL_2="260" WEIGHT="99.99999999999999" Z="7.195661537543924">
<NAME>Day 28</NAME>
<DICH_DATA CI_END="4.724845285022516" CI_START="2.341393130681758" EFFECT_SIZE="3.3260667903525047" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="28" LOG_CI_END="0.6743875921127791" LOG_CI_START="0.36947433986125444" LOG_EFFECT_SIZE="0.5219309659870168" ORDER="225" O_E="0.0" SE="0.17910755371748663" STUDY_ID="STD-Amukoye-1997" TOTAL_1="154" TOTAL_2="142" VAR="0.03207951579866236" WEIGHT="73.35532730786542"/>
<DICH_DATA CI_END="4.909489176093714" CI_START="1.1454281725771964" EFFECT_SIZE="2.371385083713851" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6910363068796332" LOG_CI_START="0.05896786067389653" LOG_EFFECT_SIZE="0.3750020837767649" ORDER="226" O_E="0.0" SE="0.3712801340905189" STUDY_ID="STD-Keuter-1990" TOTAL_1="73" TOTAL_2="82" VAR="0.1378489379702737" WEIGHT="21.344121749080138"/>
<DICH_DATA CI_END="14.196289223904799" CI_START="0.6989502568947198" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.15217483873602" LOG_CI_START="-0.15555373115681886" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="227" O_E="0.0" SE="0.7681662353158755" STUDY_ID="STD-Watkins-1988" TOTAL_1="40" TOTAL_2="36" VAR="0.590079365079365" WEIGHT="5.300550943054429"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9869185938402519" CI_END="4.100994897347671" CI_START="1.8643178856681528" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.765060240963855" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.6128892289180313" LOG_CI_START="0.2705199660763809" LOG_EFFECT_SIZE="0.4417045974972061" METHOD="MH" NO="2" P_CHI2="0.6105108552344258" P_Q="1.0" P_Z="4.253243084368146E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="284" TOTAL_2="263" WEIGHT="100.0" Z="5.05725949645598">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.690806847107636" CI_START="1.9056596526908827" EFFECT_SIZE="3.293135435992579" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="14" LOG_CI_END="0.7551738453765758" LOG_CI_START="0.28004533903217266" LOG_EFFECT_SIZE="0.5176095922043742" ORDER="228" O_E="0.0" SE="0.2790928365507402" STUDY_ID="STD-Amukoye-1997" TOTAL_1="154" TOTAL_2="142" VAR="0.07789281141393817" WEIGHT="50.086516277877465"/>
<DICH_DATA CI_END="4.387974767633693" CI_START="1.0156827145704412" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6422641215669945" LOG_CI_START="0.00675806146001366" LOG_EFFECT_SIZE="0.3245110915135041" ORDER="229" O_E="0.0" SE="0.37329940551257307" STUDY_ID="STD-Keuter-1990" TOTAL_1="82" TOTAL_2="82" VAR="0.13935244615604048" WEIGHT="30.943988720840807"/>
<DICH_DATA CI_END="6.114599218475836" CI_START="0.9716754995237435" EFFECT_SIZE="2.4375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.7863679964649355" LOG_CI_START="-0.012478747723786664" LOG_EFFECT_SIZE="0.3869446243705744" ORDER="230" O_E="0.0" SE="0.4692465318916142" STUDY_ID="STD-Watkins-1988" TOTAL_1="48" TOTAL_2="39" VAR="0.2201923076923077" WEIGHT="18.96949500128172"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="308" TOTAL_2="284" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="154" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Serious</NAME>
<DICH_DATA CI_END="2.529366219036" CI_START="0.006867535048498877" EFFECT_SIZE="0.13179723502304147" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4030117140387482" LOG_CI_START="-2.1631991154777217" LOG_EFFECT_SIZE="-0.8800937007194866" ORDER="231" O_E="0.0" SE="1.5074049442064508" STUDY_ID="STD-Amukoye-1997" TOTAL_1="154" TOTAL_2="142" VAR="2.272269665818053" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="154" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Any</NAME>
<DICH_DATA CI_END="2.529366219036" CI_START="0.006867535048498877" EFFECT_SIZE="0.13179723502304147" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4030117140387482" LOG_CI_START="-2.1631991154777217" LOG_EFFECT_SIZE="-0.8800937007194866" ORDER="232" O_E="0.0" SE="1.5074049442064508" STUDY_ID="STD-Amukoye-1997" TOTAL_1="154" TOTAL_2="142" VAR="2.272269665818053" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Three-dose regimen (with 1.2 mg chlorproguanil) versus sulfadoxine-pyrimethamine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="64" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="299" TOTAL_2="279" WEIGHT="0.0" Z="0.0">
<NAME>Parasitaemia</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="137" WEIGHT="0.0" Z="0.0">
<NAME>Day 7</NAME>
<DICH_DATA CI_END="20.32478294554737" CI_START="0.1709387562915704" EFFECT_SIZE="1.8639455782312926" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3080259163298502" LOG_CI_START="-0.7671594601854265" LOG_EFFECT_SIZE="0.2704332280722119" ORDER="233" O_E="0.0" SE="1.2189741624983574" STUDY_ID="STD-Amukoye-1997" TOTAL_1="147" TOTAL_2="137" VAR="1.4858980088385718" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="62" EVENTS_2="28" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Day 28</NAME>
<DICH_DATA CI_END="3.0345366063415304" CI_START="1.4101471965305066" EFFECT_SIZE="2.068609022556391" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="28" LOG_CI_END="0.4820923808563883" LOG_CI_START="0.14926444833224883" LOG_EFFECT_SIZE="0.31567841459431856" ORDER="234" O_E="0.0" SE="0.19550477508951647" STUDY_ID="STD-Amukoye-1997" TOTAL_1="152" TOTAL_2="142" VAR="0.03822211708280242" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="152" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.047436266028092" CI_START="1.2717778501656645" EFFECT_SIZE="2.268796992481203" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="14" LOG_CI_END="0.6071800187520975" LOG_CI_START="0.10441125685250453" LOG_EFFECT_SIZE="0.35579563780230106" ORDER="235" O_E="0.0" SE="0.29532885948533033" STUDY_ID="STD-Amukoye-1997" TOTAL_1="152" TOTAL_2="142" VAR="0.08721913524490597" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="645" TOTAL_2="623" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Haemoglobin</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlor-dap</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Day 0</NAME>
<CONT_DATA CI_END="0.461055596551589" CI_START="-0.2610555965515897" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="8.1" ORDER="236" SD_1="1.3" SD_2="1.8" SE="0.18421542405857955" STUDY_ID="STD-Amukoye-1997" TOTAL_1="152" TOTAL_2="142" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="118" WEIGHT="0.0" Z="0.0">
<NAME>Day 7</NAME>
<CONT_DATA CI_END="0.14808630067522288" CI_START="-0.7480863006752208" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="8.2" ORDER="237" SD_1="1.2" SD_2="2.2" SE="0.2286196604680848" STUDY_ID="STD-Amukoye-1997" TOTAL_1="128" TOTAL_2="118" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="129" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Day 14</NAME>
<CONT_DATA CI_END="0.5216765756721542" CI_START="-0.32167657567215485" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="8.8" ORDER="238" SD_1="1.7" SD_2="1.7" SE="0.21514506337784037" STUDY_ID="STD-Amukoye-1997" TOTAL_1="129" TOTAL_2="121" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="116" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Day 21</NAME>
<CONT_DATA CI_END="0.26622383658239857" CI_START="-0.46622383658239785" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="9.4" ORDER="239" SD_1="1.7" SD_2="1.1" SE="0.18685232967091492" STUDY_ID="STD-Amukoye-1997" TOTAL_1="116" TOTAL_2="121" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Day 28</NAME>
<CONT_DATA CI_END="0.12926178335821809" CI_START="-0.729261783358216" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="9.6" ORDER="240" SD_1="1.7" SD_2="1.7" SE="0.21901513841283776" STUDY_ID="STD-Amukoye-1997" TOTAL_1="120" TOTAL_2="121" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="304" TOTAL_2="284" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Serious</NAME>
<DICH_DATA CI_END="2.959190859305407" CI_START="0.032769817793446114" EFFECT_SIZE="0.31140350877192985" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.471172976809854" LOG_CI_START="-1.4845259733726108" LOG_EFFECT_SIZE="-0.5066764982813785" ORDER="241" O_E="0.0" SE="1.1487872442031142" STUDY_ID="STD-Amukoye-1997" TOTAL_1="152" TOTAL_2="142" VAR="1.3197121324437855" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Requiring discontinuation of treatment</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Any</NAME>
<DICH_DATA CI_END="2.959190859305407" CI_START="0.032769817793446114" EFFECT_SIZE="0.31140350877192985" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.471172976809854" LOG_CI_START="-1.4845259733726108" LOG_EFFECT_SIZE="-0.5066764982813785" ORDER="242" O_E="0.0" SE="1.1487872442031142" STUDY_ID="STD-Amukoye-1997" TOTAL_1="152" TOTAL_2="142" VAR="1.3197121324437855" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Three-dose regimen (with 2.0 mg chlorproguanil) versus sulfadoxine-pyrimethamine (previous SP failures)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Parasitaemia</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="28" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Day 7</NAME>
<DICH_DATA CI_END="0.342148920324187" CI_START="0.036670901219513885" EFFECT_SIZE="0.11201298701298701" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="28" LOG_CI_END="-0.46578482611334504" LOG_CI_START="-1.4356784167409955" LOG_EFFECT_SIZE="-0.9507316214271702" ORDER="243" O_E="0.0" SE="0.5697202961853858" STUDY_ID="STD-Mutabingwa-2001" TOTAL_1="44" TOTAL_2="46" VAR="0.3245812158855637" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3278292002283891" CI_START="0.03501699003242296" EFFECT_SIZE="0.10714285714285714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="28" LOG_CI_END="-0.48435236579522356" LOG_CI_START="-1.45572118744989" LOG_EFFECT_SIZE="-0.9700367766225568" ORDER="244" O_E="0.0" SE="0.5705868541931665" STUDY_ID="STD-Mutabingwa-2001" TOTAL_1="46" TOTAL_2="46" VAR="0.3255693581780538" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Any</NAME>
<DICH_DATA CI_END="8.325049892469536" CI_START="0.014559328127105092" EFFECT_SIZE="0.34814814814814815" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9203868449362289" LOG_CI_START="-1.836858666054806" LOG_EFFECT_SIZE="-0.45823591055928864" ORDER="245" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Mutabingwa-2001" TOTAL_1="44" TOTAL_2="46" VAR="2.6231678486997634" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Three-dose regimen (with 2.0 mg chlorproguanil) versus sulfadoxine-pyrimethamine (new attendees)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="83" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2960" TOTAL_2="740" WEIGHT="0.0" Z="0.0">
<NAME>Parasitaemia</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1480" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Day 7</NAME>
<DICH_DATA CI_END="0.6339804107785655" CI_START="0.14933356709989157" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="-0.19792416108074046" LOG_CI_START="-0.8258425608770084" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="246" O_E="0.0" SE="0.36884237628653593" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="0.13604469854469856" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="67" EVENTS_2="30" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1480" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Day 14</NAME>
<DICH_DATA CI_END="0.8457079514775633" CI_START="0.36860964895324333" EFFECT_SIZE="0.5583333333333333" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="30" LOG_CI_END="-0.07277958608534099" LOG_CI_START="-0.43343330060825574" LOG_EFFECT_SIZE="-0.2531064433467984" ORDER="247" O_E="0.0" SE="0.21184977717543937" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="0.044880328089283314" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="97" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2960" TOTAL_2="740" WEIGHT="0.0" Z="0.0">
<NAME>Presence of fever</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="13" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1480" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Day 7</NAME>
<DICH_DATA CI_END="1.423194931418743" CI_START="0.4157659385011271" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="13" LOG_CI_END="0.1532643883777301" LOG_CI_START="-0.38115109299140365" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="248" O_E="0.0" SE="0.3139182991555264" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="0.09854469854469855" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="57" EVENTS_2="9" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1480" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Day 14</NAME>
<DICH_DATA CI_END="3.168475250990353" CI_START="0.7912147786733896" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="9" LOG_CI_END="0.5008503191935292" LOG_CI_START="-0.10170560938312088" LOG_EFFECT_SIZE="0.1995723549052041" ORDER="249" O_E="0.0" SE="0.3539443351458751" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="0.12527659238185554" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5363193005839901" CI_END="0.4855708667441328" CI_START="0.18646316627023832" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30090045075023564" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.31374737792912255" LOG_CI_START="-0.7294069454395471" LOG_EFFECT_SIZE="-0.5215771616843348" METHOD="MH" NO="3" P_CHI2="0.4639622249808769" P_Q="1.0" P_Z="8.707785601332729E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="408" TOTAL_2="419" WEIGHT="100.0" Z="4.918796688274392">
<NAME>Treatment failure by day 7</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8348652457041437" CI_START="0.17408508516062174" EFFECT_SIZE="0.3812316715542522" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" LOG_CI_END="-0.07838361765400978" LOG_CI_START="-0.7592384357173121" LOG_EFFECT_SIZE="-0.41881102668566095" ORDER="250" O_E="0.0" SE="0.39993749041608845" STUDY_ID="STD-Sulo_x002d_Kenya" TOTAL_1="186" TOTAL_2="195" VAR="0.15994999624031883" WEIGHT="31.929576311574017"/>
<DICH_DATA CI_END="0.4832768366877232" CI_START="0.14336427290821938" EFFECT_SIZE="0.26321974148061106" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="46" LOG_CI_END="-0.3158040199651537" LOG_CI_START="-0.8435590635356964" LOG_EFFECT_SIZE="-0.5796815417504251" ORDER="251" O_E="0.0" SE="0.3100059250229352" STUDY_ID="STD-Sulo_x002d_Malawi" TOTAL_1="222" TOTAL_2="224" VAR="0.09610367354932572" WEIGHT="68.07042368842599"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.25884039863314" CI_END="0.5329023615680366" CI_START="0.2393191436406282" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3571186592920215" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="37" I2="44.89477960208064" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-0.27335235516968226" LOG_CI_START="-0.6210225598698337" LOG_EFFECT_SIZE="-0.44718745751975797" METHOD="MH" NO="4" P_CHI2="0.1228258145362956" P_Q="1.0" P_Z="4.6076436689129806E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1366" TOTAL_2="343" WEIGHT="100.0" Z="5.041969655309834">
<NAME>Treatment failure by day 14</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7381301668337844" CI_START="0.1543725207775589" EFFECT_SIZE="0.33756038647342995" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="-0.1318670450159269" LOG_CI_START="-0.8114300041089492" LOG_EFFECT_SIZE="-0.47164852456243805" ORDER="252" O_E="0.0" SE="0.39917864606214093" STUDY_ID="STD-Alloueche_x002d_Gabon" TOTAL_1="184" TOTAL_2="43" VAR="0.159343591472004" WEIGHT="24.614468616093273"/>
<DICH_DATA CI_END="0.3888240536601158" CI_START="0.08310058931413011" EFFECT_SIZE="0.17975402081362346" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="-0.4102468763364744" LOG_CI_START="-1.0803958963727203" LOG_EFFECT_SIZE="-0.7453213863545973" ORDER="253" O_E="0.0" SE="0.39364885166044067" STUDY_ID="STD-Alloueche_x002d_Kenya" TOTAL_1="302" TOTAL_2="76" VAR="0.15495941841358363" WEIGHT="37.73976296089771"/>
<DICH_DATA CI_END="0.8160408426380489" CI_START="0.042779687578276195" EFFECT_SIZE="0.1868421052631579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="-0.08828810437305173" LOG_CI_START="-1.368762391422418" LOG_EFFECT_SIZE="-0.7285252478977349" ORDER="254" O_E="0.0" SE="0.7521569346627439" STUDY_ID="STD-Alloueche_x002d_Malawi" TOTAL_1="285" TOTAL_2="71" VAR="0.5657400543612552" WEIGHT="10.80465347064915"/>
<DICH_DATA CI_END="2.017738646697928" CI_START="0.28451541139366554" EFFECT_SIZE="0.757679180887372" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.304864912323299" LOG_CI_START="-0.5458942041302407" LOG_EFFECT_SIZE="-0.12051464590347086" ORDER="255" O_E="0.0" SE="0.499740116330355" STUDY_ID="STD-Alloueche_x002d_Nigeria" TOTAL_1="293" TOTAL_2="74" VAR="0.2497401838698767" WEIGHT="13.468757997711071"/>
<DICH_DATA CI_END="1.7296737668169428" CI_START="0.22787599678264622" EFFECT_SIZE="0.6278145695364239" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.23796419871746374" LOG_CI_START="-0.64230141862767" LOG_EFFECT_SIZE="-0.20216860995510313" ORDER="256" O_E="0.0" SE="0.5170723810136124" STUDY_ID="STD-Alloueche_x002d_Tanzania" TOTAL_1="302" TOTAL_2="79" VAR="0.26736384720708634" WEIGHT="13.372356954648794"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="3018" TOTAL_2="750" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Haemoglobin</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlor-dap</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1479" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Day 0</NAME>
<CONT_DATA CI_END="0.023299457992699113" CI_START="-0.4232994579926977" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.6" ORDER="257" SD_1="1.96" SD_2="1.96" SE="0.1139303883918562" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1479" TOTAL_2="370" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1364" TOTAL_2="337" WEIGHT="0.0" Z="0.0">
<NAME>Day 7</NAME>
<CONT_DATA CI_END="-0.1768069964322507" CI_START="-0.62319300356775" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="9.3" ORDER="258" SD_1="1.88" SD_2="1.87" SE="0.11387607391169816" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1364" TOTAL_2="337" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Day 14</NAME>
<CONT_DATA CI_END="0.23773220280029939" CI_START="-0.8377322028002973" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.7" ORDER="259" SD_1="1.35" SD_2="1.67" SE="0.27435820609044925" STUDY_ID="STD-Alloueche-2004" TOTAL_1="175" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="16.10908235565628" CI_END="1.1396952627015093" CI_START="0.9134435472189327" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.020317246502616" ESTIMABLE="YES" EVENTS_1="779" EVENTS_2="258" I2="62.75393056207663" I2_Q="79.6458521435305" ID="CMP-005.06" LOG_CI_END="0.05678874307400592" LOG_CI_START="-0.0393182878176238" LOG_EFFECT_SIZE="0.008735227628191062" METHOD="MH" NO="6" P_CHI2="0.013180334588803966" P_Q="0.0073503915956002475" P_Z="0.7216273791377166" Q="9.826007033570345" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2710" TOTAL_2="1627" WEIGHT="300.0" Z="0.35628468363191973">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.10371224908327434" CI_END="1.607513249579763" CI_START="0.6149870355782822" DF="1" EFFECT_SIZE="0.9942835651924806" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.2061545611892081" LOG_CI_START="-0.21113403940532985" LOG_EFFECT_SIZE="-0.002489739108060827" NO="1" P_CHI2="0.7474194961311699" P_Z="0.9813406772659805" STUDIES="2" TAU2="0.0" TOTAL_1="410" TOTAL_2="419" WEIGHT="100.0" Z="0.02338812503263945">
<NAME>Serious</NAME>
<DICH_DATA CI_END="1.6884658737066731" CI_START="0.5215907120014784" EFFECT_SIZE="0.9384498480243161" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.22749228735185437" LOG_CI_START="-0.2826701507163587" LOG_EFFECT_SIZE="-0.027588931682252165" ORDER="260" O_E="0.0" SE="0.299671941466065" STUDY_ID="STD-Sulo_x002d_Kenya" TOTAL_1="188" TOTAL_2="195" VAR="0.0898032725020407" WEIGHT="67.43631341657895"/>
<DICH_DATA CI_END="2.560726263271035" CI_START="0.4810744614860211" EFFECT_SIZE="1.10990990990991" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4083631557020084" LOG_CI_START="-0.31778769761850995" LOG_EFFECT_SIZE="0.045287729041749214" ORDER="261" O_E="0.0" SE="0.42654460574516784" STUDY_ID="STD-Sulo_x002d_Malawi" TOTAL_1="222" TOTAL_2="224" VAR="0.18194030069030068" WEIGHT="32.56368658342104"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.012236791275483034" CI_END="11.820018471329144" CI_START="1.741508370659262" DF="1" EFFECT_SIZE="4.537032191771048" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="5" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="1.0726181552245981" LOG_CI_START="0.240925566260457" LOG_EFFECT_SIZE="0.6567718607425275" NO="2" P_CHI2="0.9119176640040056" P_Z="0.0019648617088733927" STUDIES="2" TAU2="0.0" TOTAL_1="410" TOTAL_2="419" WEIGHT="100.0" Z="3.0954927582508747">
<NAME>Requiring discontinuation of treatment</NAME>
<DICH_DATA CI_END="12.859512183031557" CI_START="1.51114761506222" EFFECT_SIZE="4.408244680851064" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="1.109224494230829" LOG_CI_START="0.17930689006747055" LOG_EFFECT_SIZE="0.6442656921491497" ORDER="262" O_E="0.0" SE="0.5462382038519362" STUDY_ID="STD-Sulo_x002d_Kenya" TOTAL_1="188" TOTAL_2="195" VAR="0.2983761753473894" WEIGHT="79.7758421380626"/>
<DICH_DATA CI_END="42.836950231980175" CI_START="0.5941711389045586" EFFECT_SIZE="5.045045045045045" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6318185437524968" LOG_CI_START="-0.22608844731341093" LOG_EFFECT_SIZE="0.702865048219543" ORDER="263" O_E="0.0" SE="1.0913437633400438" STUDY_ID="STD-Sulo_x002d_Malawi" TOTAL_1="222" TOTAL_2="224" VAR="1.1910312097812097" WEIGHT="20.224157861937407"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.1194517809589914" CI_END="1.0870389061326342" CI_START="0.8667174620866849" DF="2" EFFECT_SIZE="0.9706470017018354" ESTIMABLE="YES" EVENTS_1="727" EVENTS_2="222" I2="60.93331697275301" ID="CMP-005.06.03" LOG_CI_END="0.03624508816756132" LOG_CI_START="-0.06212245345172441" LOG_EFFECT_SIZE="-0.012938682642081539" NO="3" P_CHI2="0.07732602654261311" P_Z="0.6061309751446098" STUDIES="3" TAU2="0.0" TOTAL_1="1890" TOTAL_2="789" WEIGHT="99.99999999999999" Z="0.5156040614295776">
<NAME>Any</NAME>
<DICH_DATA CI_END="1.0244505224780407" CI_START="0.8121815469113449" EFFECT_SIZE="0.9121621621621622" ESTIMABLE="YES" EVENTS_1="675" EVENTS_2="185" LOG_CI_END="0.010490988277817526" LOG_CI_START="-0.09034688207772007" LOG_EFFECT_SIZE="-0.039927946899951265" ORDER="264" O_E="0.0" SE="0.05923266420235129" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="0.0035085085085085083" WEIGHT="89.02542949440472"/>
<DICH_DATA CI_END="2.388080786288012" CI_START="0.9341776957700109" EFFECT_SIZE="1.4936170212765958" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="25" LOG_CI_END="0.3780490144362449" LOG_CI_START="-0.029570506048069222" LOG_EFFECT_SIZE="0.17423925419408784" ORDER="265" O_E="0.0" SE="0.2394377240816543" STUDY_ID="STD-Sulo_x002d_Kenya" TOTAL_1="188" TOTAL_2="195" VAR="0.057330423713402426" WEIGHT="7.381615952009424"/>
<DICH_DATA CI_END="2.778034045139308" CI_START="0.6515233682644175" EFFECT_SIZE="1.3453453453453454" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.443737563765001" LOG_CI_START="-0.1860700027813527" LOG_EFFECT_SIZE="0.12883378049182417" ORDER="266" O_E="0.0" SE="0.36995208218706255" STUDY_ID="STD-Sulo_x002d_Malawi" TOTAL_1="222" TOTAL_2="224" VAR="0.13686454311454307" WEIGHT="3.592954553585841"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="5920" TOTAL_2="1480" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events (Alloueche 2004)</NAME>
<GROUP_LABEL_1>Chlor-dap</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlor-dap</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1480" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Red blood cell disorders</NAME>
<DICH_DATA CI_END="19.467748967091175" CI_START="0.3210437945632633" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.2893157374630866" LOG_CI_START="-0.49343572011901127" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="267" O_E="0.0" SE="1.0471970309457632" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="1.0966216216216218" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-005.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1480" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Convulsions</NAME>
<DICH_DATA CI_END="2.7193807282748517" CI_START="0.09193269533780858" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.4344700154630073" LOG_CI_START="-1.0365300067909697" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="268" O_E="0.0" SE="0.8640726946395318" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="0.7466216216216216" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1480" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Other</NAME>
<DICH_DATA CI_END="5.49920709767201" CI_START="0.04546109931117759" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.7403000753251909" LOG_CI_START="-1.3423600666531534" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="269" O_E="0.0" SE="1.223364876732049" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="1.4966216216216217" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="4" I2="0.0" ID="CMP-005.07.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1480" TOTAL_2="370" WEIGHT="0.0" Z="0.0">
<NAME>Total serious "Treatment Emergent Signs and Symptoms (TESS)" (as described by author)</NAME>
<DICH_DATA CI_END="2.973425432173553" CI_START="0.3363124526950074" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.47325705169636256" LOG_CI_START="-0.4732570516963625" LOG_EFFECT_SIZE="0.0" ORDER="270" O_E="0.0" SE="0.5559870696532624" STUDY_ID="STD-Alloueche-2004" TOTAL_1="1480" TOTAL_2="370" VAR="0.3091216216216216" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>